Physician profile
Diviyesh B Patel
NPI 1609211853
$5,652.60
in general payments reported to CMS, 2019-2025
24 companies · $920 in 2025
The $920 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $313 · 2021: $508 · 2022: $1,125 · 2023: $1,396 · 2024: $1,021 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.75 |
| Entertainment | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $985.48 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $817.25 | 2019-2024 | Rocklatan, Simbrinza, Rhopressa |
| Bausch & Lomb Americas INC. | $536.60 | 2022-2025 | Xiidra, Miebo, Infuse |
| Novartis Pharmaceuticals Corporation | $472.54 | 2019-2023 | |
| Biotissue Holdings INC. | $380.76 | 2022-2024 | |
| Sight Sciences, INC. | $275.83 | 2022-2025 | Tearcare System |
| Oyster Point Pharma, INC. | $256.24 | 2023-2025 | Tyrvaya |
| Harrow Eye, LLC | $225.80 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $214.51 | 2025 | Xdemvy |
| Optos, INC. | $211.00 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $177.79 | 2024-2025 | Oxervate |
| Abbvie INC. | $158.56 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $154.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $113.88 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $104.03 | 2020-2021 | |
| Lkc Technologies, INC. | $102.74 | 2024 | |
| Coopervision INC. | $86.03 | 2023 | Myday Contact Lens |
| Carl Zeiss Meditec USA, INC. | $57.58 | 2021 | |
| Tearlab Corp | $23.85 | 2024 | Scoutpro Osmolarity System |
| Rayner Intraocular Lenses Limited | $20.58 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $19.82 | 2019 | |
| Shire North American Group INC | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diviyesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.